This week we’re focusing on MASH. It’s a high area of unmet medical need, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development.

The Pharma Letter Podcast — Episode 28 — Breakthroughs in MASH, with 89bio CEO | Biotechnology | The Pharmaletter | The Pharmaletter

The Pharma Letter Podcast — Episode 28 — Breakthroughs in MASH, with 89bio CEO

column-header-date-desktop-only-1

column-header-logo-1

column-header-secondary-menu-desktop-only-1

row-header-1

row-header-and-main-menu-1

row-menu-container-1

code-sticky-header-1

row-header-background-1

banner-leaderboard

row-leaderboard

row-leaderboard-banner-bg-container

breadcrumb

row-breadcrumb

datasummary-page-title

row-title-row

row-row-category-date-container

row-category-date

column-main

column-sidebar

row-main-section

card-more-features-in-category

row-other-related

code-banner-spacer-3

banner-billboard-bottom

row-billboard-bottom

row-page

footer-first-column-2

footer-second-column-2

footer-third-column-2

row-footer-2

row-footer-container-2

textblock-copyright

row-copyright

backtotop-1

gtm-user-all-block

structured-data-component-header-auto

The Pharma Letter Podcast — Episode 28 — Breakthroughs in MASH, with 89bio CEO

More on this story...

Companies featured in this story

Today's issue

Company Spotlight

More Features in Biotechnology